26207797|t|The antioxidant effect of ubiquinone and combined therapy on mitochondrial function in blood cells in non-proliferative diabetic retinopathy: A randomized, double-blind, phase IIa, placebo-controlled study.
26207797|a|OBJECTIVES: To evaluate the effect of ubiquinone and combined antioxidant therapy on mitochondrial function in non-proliferative diabetic retinopathy (NPDR) in a randomized, double-blind, phase IIa, placebo-controlled, clinical trial. Three groups of 20 patients were formed: Group 1, ubiquinone; Group 2, combined therapy; and Group 3, placebo (one daily dose for 6 months). METHODS: Fluidity of the submitochondrial membrane in platelets was determined by examining intensity of fluorescence between the monomer (Im) and excimer (Ie). Hydrolytic activity of the mitochondrial F0F1-ATPase was evaluated with the spectrophotometric method. RESULTS: Normal, baseline submitochondrial membrane fluidity, 0.24 +- 0.01 Ie/Im, was significantly diminished in the three study groups vs. normal values (P < 0.0001); placebo, 0.14 +- 0.01 Ie/Im; ubiquinone, 0.14 +- 0.01 Ie/Im; and combined therapy, 0.13 +- 0.00 Ie/Im. Afterward, it increased significantly (P < 0.0001), the ubiquinone group 0.22 +- 0.01 Ie/Im, combined therapy group, 0.19 +- 0.01 Ie/Im; with no changes the placebo group. Baseline hydrolytic activity of the F0F1-ATPase enzyme increased in the three study groups vs. normal values (184.50 +- 7.84 nmol PO4), placebo, 304.12 +- 22.83 nmol PO4 (P < 0.002); ubiquinone, 312.41 +- 25.63 nmol PO4 (P < 0.009); and combined therapy, 371.28 +- 33.50 nmol PO4 (P < 0.002). Afterward, a significant decrease the enzymatic activity: ubiquinone, 213.25 +- 14.19 nmol PO4 (P < 0.001); and combined therapy, 225.55 +- 14.48 nmol PO4 (P < 0.0001). DISCUSSION: Mitochondrial dysfunction significantly improved in groups of NPDR patients treated with antioxidants.
26207797	26	36	ubiquinone	Chemical	MESH:D014451
26207797	102	140	non-proliferative diabetic retinopathy	Disease	OMIM:603933
26207797	245	255	ubiquinone	Chemical	MESH:D014451
26207797	318	356	non-proliferative diabetic retinopathy	Disease	OMIM:603933
26207797	358	362	NPDR	Disease	OMIM:603933
26207797	461	469	patients	Species	9606
26207797	492	502	ubiquinone	Chemical	MESH:D014451
26207797	785	796	F0F1-ATPase	Gene	514
26207797	1045	1055	ubiquinone	Chemical	MESH:D014451
26207797	1175	1185	ubiquinone	Chemical	MESH:D014451
26207797	1327	1338	F0F1-ATPase	Gene	514
26207797	1421	1424	PO4	Chemical	-
26207797	1457	1460	PO4	Chemical	-
26207797	1474	1484	ubiquinone	Chemical	MESH:D014451
26207797	1507	1510	PO4	Chemical	-
26207797	1567	1570	PO4	Chemical	-
26207797	1642	1652	ubiquinone	Chemical	MESH:D014451
26207797	1675	1678	PO4	Chemical	-
26207797	1735	1738	PO4	Chemical	-
26207797	1765	1790	Mitochondrial dysfunction	Disease	MESH:D028361
26207797	1827	1831	NPDR	Disease	OMIM:603933
26207797	1832	1840	patients	Species	9606
26207797	Positive_Correlation	MESH:D014451	514
26207797	Negative_Correlation	MESH:D014451	OMIM:603933

